<p>AMI 资产管理公司在第四季度购买了 Vera Therapeutics, Inc.（纳斯达克代码：VERA - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）的披露，该公司购买了 28,523 股该公司的股票，价值约为 1,444,000 美元。</p>
<p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<ul>
<li>分析师们对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>其他几家大型投资者最近也增加或减少了对该股票的持股。德尔菲德管理公司在第三季度将其在 Vera Therapeutics 的持股增加了 8.8%。德尔菲德管理公司目前拥有 3,641,157 股该公司的股票，价值为 105,812,000 美元，在此期间又购买了 293,040 股。先锋集团在第三季度将其在 Vera Therapeutics 的持股增加了 6.3%。先锋集团目前拥有 3,190,653 股该公司的股票，价值为 92,720,000 美元，在上个季度又购买了 189,545 股。Vestal Point Capital LP 在第二季度将其在 Vera Therapeutics 的持股增加了 24.0%。Vestal Point Capital LP 目前拥有 3,100,000 股该公司的股票，价值为 73,036,000 美元，在上个季度又购买了 600,000 股。Integral Health Asset Management LLC 在第三季度将其在 Vera Therapeutics 的持股增加了 47.8%。Integral Health Asset Management LLC 目前拥有 1,700,000 股该公司的股票，价值为 49,402,000 美元，在上个季度又购买了 550,000 股。最后，施罗德投资管理集团在第三季度将其在 Vera Therapeutics 的持股增加了 82.4%。施罗德投资管理集团目前拥有 679,992 股该公司的股票，价值为 19,652,000 美元，在上个季度又购买了 307,243 股。99.21% 的股票由机构投资者和对冲基金持有。</p>
<h2>Vera Therapeutics 股价下跌 3.0%</h2>
<p>VERA 股票周二开盘价为 43.71 美元。该股票的 50 日简单移动平均线为 41.19 美元，200 日简单移动平均线为 39.35 美元。Vera Therapeutics, Inc.的 52 周低点为 18.76 美元，52 周高点为 56.05 美元。该公司的市值为 31.2 亿美元，市盈率为-9.38，贝塔值为 1.17。该公司的速动比率为 13.64，流动比率为 13.64，债务与股本比率为 0.12。</p>
<p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）最后一次公布财报是在 2 月 26 日，星期四。该公司报告本季度每股收益为（1.39 美元），低于市场共识预期的（1.34 美元）0.05 美元。去年同期，该公司每股收益为（0.72 美元）。分析师平均预计 Vera Therapeutics, Inc.在当前财政年度将发布每股收益-2.89 美元。</p>
<h2>Vera Therapeutics 的内部买卖</h2>
<p>在相关消息中，首席执行官 Marshall Fordyce 在 2 月 23 日星期一以 41.98 美元的平均价格出售了 16,925 股该股票，总价值为 710,511.50 美元。交易完成后，首席执行官持有 257,163 股公司股票，价值为 10,795,702.74 美元。这笔交易代表其持股减少了 6.18%。该交易已在向 SEC 提交的文件中披露，可以通过 SEC 网站访问。此外，高级副总裁 Joseph R. Young 在 2 月 23 日星期一以 41.98 美元的平均价格出售了 3,117 股该股票，总价值为 130,851.66 美元。交易完成后，高级副总裁持有 64,722 股该公司的股票，价值为 2,717,029.56 美元。这笔交易代表其持股减少了 4.59%。该销售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售 33,490 股公司股票，价值为 1,405,910 美元。公司内部人士持有 16.30% 的公司股票。</p>
<h2>分析师的升级和降级</h2>
<p>VERA 最近成为几份分析师报告的主题。摩根大通将 Vera Therapeutics 的目标价从 99.00 美元下调至 96.00 美元，并在 12 月 19 日的研究报告中给予该公司 “增持” 评级。美国银行将 Vera Therapeutics 的目标价从 48.00 美元上调至 66.00 美元，并在 12 月 19 日的研究报告中给予该股票 “买入” 评级。Wolfe Research 将 Vera Therapeutics 的评级从 “同行表现” 上调至 “跑赢大盘”，并在 3 月 11 日的研究报告中设定了 88.00 美元的目标价。HC Wainwright 将 Vera Therapeutics 的目标价从 90.00 美元上调至 110.00 美元，并在 3 月 2 日的研究报告中给予该股票 “买入” 评级。最后，高盛集团将 Vera Therapeutics 的目标价从 55.00 美元上调至 95.00 美元，并在 12 月 19 日的研究报告中给予该股票 “买入” 评级。十位投资分析师对该股票给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 81.45 美元。</p>
<p><strong>获取我们对 Vera Therapeutics 的最新分析</strong></p>
<h2>关于 Vera Therapeutics</h2>
<p>（免费报告）</p>
<p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用身体自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，该公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、改变疾病进程的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
<p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥，与领先的学术和研究机构合作，推进其开发项目。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Vera Therapeutics 吗？</h2>
<p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERA

生物科技 ETF - VanEck Vectors

标普全球医疗股指数 ETF - iShares

<p>AMI 资产管理公司已投资 144 万美元于 Vera Therapeutics，收购 28,523 股。其他机构投资者，包括 Deerfield Management 和 Vanguard Group，也增加了他们的持股。Vera 的股票目前交易价格为 43.71 美元，下跌 3.0%，市值为 31.2 亿美元。该公司在最近的财报中报告每股亏损 1.39 美元。内部交易活动包括首席执行官 Marshall Fordyce 和高级副总裁 Joseph R. Young 的股票出售。分析师的评级不一，目标价格范围从 66 美元到 110 美元</p>

<p>AMI Asset Management Corp bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 28,523 shares of the company's stock, valued at approximately $1,444,000.</p>
<div class="lb-trans"><p>AMI 资产管理公司在第四季度购买了 Vera Therapeutics, Inc.（纳斯达克代码：VERA - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）的披露，该公司购买了 28,523 股该公司的股票，价值约为 1,444,000 美元。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师们对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. increased its position in Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company's stock worth $105,812,000 after buying an additional 293,040 shares during the period. Vanguard Group Inc. grew its stake in shares of Vera Therapeutics by 6.3% in the third quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company's stock worth $92,720,000 after purchasing an additional 189,545 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company's stock worth $73,036,000 after purchasing an additional 600,000 shares in the last quarter. Integral Health Asset Management LLC grew its stake in shares of Vera Therapeutics by 47.8% in the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company's stock worth $49,402,000 after purchasing an additional 550,000 shares in the last quarter. Finally, Schroder Investment Management Group grew its stake in shares of Vera Therapeutics by 82.4% in the third quarter. Schroder Investment Management Group now owns 679,992 shares of the company's stock worth $19,652,000 after purchasing an additional 307,243 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了对该股票的持股。德尔菲德管理公司在第三季度将其在 Vera Therapeutics 的持股增加了 8.8%。德尔菲德管理公司目前拥有 3,641,157 股该公司的股票，价值为 105,812,000 美元，在此期间又购买了 293,040 股。先锋集团在第三季度将其在 Vera Therapeutics 的持股增加了 6.3%。先锋集团目前拥有 3,190,653 股该公司的股票，价值为 92,720,000 美元，在上个季度又购买了 189,545 股。Vestal Point Capital LP 在第二季度将其在 Vera Therapeutics 的持股增加了 24.0%。Vestal Point Capital LP 目前拥有 3,100,000 股该公司的股票，价值为 73,036,000 美元，在上个季度又购买了 600,000 股。Integral Health Asset Management LLC 在第三季度将其在 Vera Therapeutics 的持股增加了 47.8%。Integral Health Asset Management LLC 目前拥有 1,700,000 股该公司的股票，价值为 49,402,000 美元，在上个季度又购买了 550,000 股。最后，施罗德投资管理集团在第三季度将其在 Vera Therapeutics 的持股增加了 82.4%。施罗德投资管理集团目前拥有 679,992 股该公司的股票，价值为 19,652,000 美元，在上个季度又购买了 307,243 股。99.21% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Vera Therapeutics Trading Down 3.0%</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股价下跌 3.0%</h2>
</div><p>Shares of VERA stock opened at $43.71 on Tuesday. The stock has a 50-day simple moving average of $41.19 and a 200 day simple moving average of $39.35. Vera Therapeutics, Inc. has a fifty-two week low of $18.76 and a fifty-two week high of $56.05. The stock has a market capitalization of $3.12 billion, a P/E ratio of -9.38 and a beta of 1.17. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12.</p>
<div class="lb-trans"><p>VERA 股票周二开盘价为 43.71 美元。该股票的 50 日简单移动平均线为 41.19 美元，200 日简单移动平均线为 39.35 美元。Vera Therapeutics, Inc.的 52 周低点为 18.76 美元，52 周高点为 56.05 美元。该公司的市值为 31.2 亿美元，市盈率为-9.38，贝塔值为 1.17。该公司的速动比率为 13.64，流动比率为 13.64，债务与股本比率为 0.12。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter last year, the company earned ($0.72) earnings per share. On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）最后一次公布财报是在 2 月 26 日，星期四。该公司报告本季度每股收益为（1.39 美元），低于市场共识预期的（1.34 美元）0.05 美元。去年同期，该公司每股收益为（0.72 美元）。分析师平均预计 Vera Therapeutics, Inc.在当前财政年度将发布每股收益-2.89 美元。</p>
</div><h2>Insider Buying and Selling at Vera Therapeutics</h2>
<div class="lb-trans"><h2>Vera Therapeutics 的内部买卖</h2>
</div><p>In related news, CEO Marshall Fordyce sold 16,925 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $710,511.50. Following the completion of the transaction, the chief executive officer owned 257,163 shares in the company, valued at $10,795,702.74. This trade represents a 6.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Joseph R. Young sold 3,117 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the transaction, the senior vice president owned 64,722 shares of the company's stock, valued at $2,717,029.56. This trade represents a 4.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 33,490 shares of company stock valued at $1,405,910. Corporate insiders own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Marshall Fordyce 在 2 月 23 日星期一以 41.98 美元的平均价格出售了 16,925 股该股票，总价值为 710,511.50 美元。交易完成后，首席执行官持有 257,163 股公司股票，价值为 10,795,702.74 美元。这笔交易代表其持股减少了 6.18%。该交易已在向 SEC 提交的文件中披露，可以通过 SEC 网站访问。此外，高级副总裁 Joseph R. Young 在 2 月 23 日星期一以 41.98 美元的平均价格出售了 3,117 股该股票，总价值为 130,851.66 美元。交易完成后，高级副总裁持有 64,722 股该公司的股票，价值为 2,717,029.56 美元。这笔交易代表其持股减少了 4.59%。该销售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售 33,490 股公司股票，价值为 1,405,910 美元。公司内部人士持有 16.30% 的公司股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>VERA has been the subject of several recent analyst reports. JPMorgan Chase &amp; Co. decreased their price target on Vera Therapeutics from $99.00 to $96.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, December 19th. Bank of America increased their price target on Vera Therapeutics from $48.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, December 19th. Wolfe Research raised Vera Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. HC Wainwright increased their price target on Vera Therapeutics from $90.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, March 2nd. Finally, The Goldman Sachs Group increased their price target on Vera Therapeutics from $55.00 to $95.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, December 19th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $81.45.</p>
<div class="lb-trans"><p>VERA 最近成为几份分析师报告的主题。摩根大通将 Vera Therapeutics 的目标价从 99.00 美元下调至 96.00 美元，并在 12 月 19 日的研究报告中给予该公司 “增持” 评级。美国银行将 Vera Therapeutics 的目标价从 48.00 美元上调至 66.00 美元，并在 12 月 19 日的研究报告中给予该股票 “买入” 评级。Wolfe Research 将 Vera Therapeutics 的评级从 “同行表现” 上调至 “跑赢大盘”，并在 3 月 11 日的研究报告中设定了 88.00 美元的目标价。HC Wainwright 将 Vera Therapeutics 的目标价从 90.00 美元上调至 110.00 美元，并在 3 月 2 日的研究报告中给予该股票 “买入” 评级。最后，高盛集团将 Vera Therapeutics 的目标价从 55.00 美元上调至 95.00 美元，并在 12 月 19 日的研究报告中给予该股票 “买入” 评级。十位投资分析师对该股票给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 81.45 美元。</p>
</div><p><strong>Get Our Latest Analysis on Vera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Vera Therapeutics 的最新分析</strong></p>
</div><h2>About Vera Therapeutics</h2>
<div class="lb-trans"><h2>关于 Vera Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.</p>
<div class="lb-trans"><p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用身体自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，该公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、改变疾病进程的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
</div><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p>
<div class="lb-trans"><p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥，与领先的学术和研究机构合作，推进其开发项目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AMI Asset Management Corp Makes New $1.44 Million Investment in Vera Therapeutics, Inc. $VERA

Market Beat

Vera Therapeutics

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

AMI 资产管理公司对 Vera Therapeutics, Inc. $VERA 进行了新的 144 万美元投资